Meeting
2022 ASCO Gastrointestinal Cancers Symposium
Natural history of patients with advanced cholangiocarcinoma and FGFR2 gene fusions/rearrangements.
Authors
Rachna T. Shroff
University of Arizona Cancer Center, Tucson, AZ
Rachna T. Shroff , Francesca Avogadri , Richard Weng , Ai Li , Carl L. Dambkowski , Angela Lamarca
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Poster Session B: Cancers of the Pancreas, Small Bowel, and Hepatobiliary Tract
Track
Pancreatic Cancer,Hepatobiliary Cancer,Neuroendocrine/Carcinoid,Small Bowel Cancer
Sub Track
Patient-Reported Outcomes and Real-World Evidence
Clinical Trial Registration Number
PhR-001
DOI
10.1200/JCO.2022.40.4_suppl.391
Abstract #
391
Poster Bd #
A5
Abstract Disclosures
Similar Posters
Poster
2021 ASCO Annual Meeting
Natural history of patients (pts) with advanced cholangiocarcinoma (CCA) with FGFR2 gene fusion/rearrangement or wild-type (WT) FGFR2.
First Author: Rachna T. Shroff
Poster
2020 ASCO Virtual Scientific Program
A retrospective analysis of post second-line chemotherapy treatment outcomes for patients with advanced or metastatic cholangiocarcinoma and FGFR2 fusions.
First Author: Milind M. Javle
Poster
2020 Gastrointestinal Cancers Symposium
Progression-free survival in patients with cholangiocarcinoma with FGFR2 fusions or rearrangements: An exploration of response to systemic therapy.
First Author: Kristen Bibeau
Poster
2024 ASCO Gastrointestinal Cancers Symposium
Real-world use of pemigatinib (pemi) for cholangiocarcinoma (CCA) among racial and ethnic minorities in the United States.
First Author: Richard D. Kim